Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group - PubMed (original) (raw)
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group
Anglian Breast Cancer Study Group. Br J Cancer. 2000 Nov.
Abstract
Estimates of the contribution of BRCA1 and BRCA2 to breast cancer incidence in outbred populations have been based on studies that are either small or have selected for cases diagnosed at an early age. Only one of these has reported an estimate of the breast cancer risk associated with a mutation in these genes, and there is no published ovarian cancer risk estimate derived from a population-based case series. We screened a population-based series of breast cancer cases diagnosed before the age of 55 for mutations in BRCA1 and BRCA2. Pedigree information from the mutation carriers was used to estimate penetrance and the proportion of familial risk of breast cancer due to BRCA1 and BRCA2. We identified eight (0.7%) BRCA1 and 16 (1.3%) BRCA2 mutation carriers in 1220 breast cancer cases (actual sample size 1435 adjusted for 15% polymerase chain reaction failure rate). Mutation prevalence was substantially higher in cases diagnosed before 35 years-of-age and with increasing number of relatives affected with breast or ovarian cancer. However, most mutation carriers were diagnosed in the older age groups, and a minority reported a first-degree relative with breast cancer. Breast cancer penetrance by age 80 was estimated to be 48% (95% CI 7-82%) for BRCA1 mutation carriers and 74% (7-94%) for BRCA2 mutation carriers. Ovarian cancer penetrance for BRCA1 and BRCA2 combined was 22% (6-65%) by age 80. 17% of the familial risk of breast cancer was attributable to BRCA1 and BRCA2. At birth, the estimated prevalence of BRCA1 mutation carriers was 0.07% or 0.09% depending on the penetrance function used for the calculation. For BRCA2, the birth prevalence estimates were 0.14% and 0.22%. Mutations in the genes BRCA1 and BRCA2 are rare in the population and account for a small fraction of all breast cancer in the UK. They account for less than one fifth of the familial risk of breast cancer. Eligibility criteria for BRCA1 and BRCA2 mutation testing based on family history and age of onset will identify only a small proportion of mutation carriers.
Copyright 2000 Cancer Research Campaign.
Similar articles
- Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Antoniou AC, et al. Genet Epidemiol. 2001 Jul;21(1):1-18. doi: 10.1002/gepi.1014. Genet Epidemiol. 2001. PMID: 11443730 - Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Risch HA, et al. Am J Hum Genet. 2001 Mar;68(3):700-10. doi: 10.1086/318787. Epub 2001 Feb 15. Am J Hum Genet. 2001. PMID: 11179017 Free PMC article. - Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR. Peto J, et al. J Natl Cancer Inst. 1999 Jun 2;91(11):943-9. doi: 10.1093/jnci/91.11.943. J Natl Cancer Inst. 1999. PMID: 10359546 - Breast cancer susceptibility genes. BRCA1 and BRCA2.
Brody LC, Biesecker BB. Brody LC, et al. Medicine (Baltimore). 1998 May;77(3):208-26. doi: 10.1097/00005792-199805000-00006. Medicine (Baltimore). 1998. PMID: 9653432 Review. - Genetic Tests for Breast and Ovarian Cancer [Internet].
Juvet LK, Natvig Norderhaug I. Juvet LK, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb. Report from Norwegian Knowledge Centre for the Health Services (NOKC) No. 05-2008. PMID: 29319983 Free Books & Documents. Review.
Cited by
- Fertility Preservation in BRCA1/2 Germline Mutation Carriers: An Overview.
Silvestris E, Cormio G, Loizzi V, Corrado G, Arezzo F, Petracca EA. Silvestris E, et al. Life (Basel). 2024 May 10;14(5):615. doi: 10.3390/life14050615. Life (Basel). 2024. PMID: 38792636 Free PMC article. Review. - Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
Ben-Zion Berliner M, Yust-Katz S, Lavie I, Goldberg Y, Kedar I, Yerushalmi R. Ben-Zion Berliner M, et al. BMC Cancer. 2024 Feb 16;24(1):219. doi: 10.1186/s12885-024-11975-7. BMC Cancer. 2024. PMID: 38365640 Free PMC article. - Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
Guo F, Adekanmbi V, Hsu CD, Berenson AB, Kuo YF, Shih YT. Guo F, et al. JAMA Netw Open. 2024 Feb 5;7(2):e2356078. doi: 10.1001/jamanetworkopen.2023.56078. JAMA Netw Open. 2024. PMID: 38353949 Free PMC article. - Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants - an Asian study of 572 families.
Ho WK, Hassan NT, Yoon SY, Yang X, Lim JMC, Binte Ishak ND, Ho PJ, Wijaya EA, Ng PP, Luccarini C, Allen J, Tai MC, Chiang J, Zhang Z, See MH, Thong MK, Woo YL, Dunning AM, Hartman M, Yip CH, Mohd Taib NA, Easton DF, Li J, Ngeow J, Antoniou AC, Teo SH. Ho WK, et al. Lancet Reg Health West Pac. 2024 Feb 5;44:101017. doi: 10.1016/j.lanwpc.2024.101017. eCollection 2024 Mar. Lancet Reg Health West Pac. 2024. PMID: 38333895 Free PMC article.
References
- Lancet. 1994 Mar 19;343(8899):692-5 - PubMed
- Int J Epidemiol. 1986 Mar;15(1):134-7 - PubMed
- Am J Hum Genet. 1995 Jan;56(1):265-71 - PubMed
- Nat Genet. 1995 Oct;11(2):198-200 - PubMed
- Am J Hum Genet. 1995 Dec;57(6):1457-62 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous